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C A N C E R
Dual complementary liposomes inhibit triple-negative 
breast tumor progression and metastasis
Peng Guo1,2,3*, Jiang Yang1,2*†, Daxing Liu3‡, Lan Huang1,2, Gillian Fell1,2, Jing Huang1,2, 
Marsha A. Moses1,2§‖, Debra T. Auguste3‡§‖
Distinguishing malignant cells from non-neoplastic ones is a major challenge in triple-negative breast cancer 
(TNBC) treatment. Here, we developed a complementary targeting strategy that uses precisely matched, 
multivalent ligand-receptor interactions to recognize and target TNBC tumors at the primary site and metastatic 
lesions. We screened a panel of cancer cell surface markers and identified intercellular adhesion molecule–1 
(ICAM1) and epithelial growth factor receptor (EGFR) as optimal candidates for TNBC complementary targeting. 
We engineered a dual complementary liposome (DCL) that precisely complements the molecular ratio and organi-
zation of ICAM1 and EGFR specific to TNBC cell surfaces. Our in vitro mechanistic studies demonstrated that 
DCLs, compared to single-targeting liposomes, exhibited increased binding, enhanced internalization, and decreased 
receptor signaling. DCLs consistently exhibited substantially increased tumor targeting activity and antitumor 
efficacy in orthotopic and lung metastasis models, indicating that DCLs are a platform technology for the design 
of personalized nanomedicines for TNBC.
INTRODUCTION
Triple-negative breast cancer (TNBC) is a heterogeneous disease, 
defined by the lack of estrogen receptor, progesterone receptor, and 
human epidermal growth factor receptor type 2. TNBC, which rep-
resents 15 to 20% of all breast cancers, occurs more frequently in 
women under 50 years of age, in African American women, and in 
individuals carrying a breast cancer early onset 1 (BRCA1) gene mu-
tation (1, 2). Because of the lack of therapeutic targets and limited 
treatment options, the prognosis for patients with TNBC remains 
the poorest among all patients with breast cancer (2–4).
Nanotherapeutics were developed to improve the safety and ef-
ficacy of antitumor drugs, which bring measurable clinical benefits 
to the treatment of several metastatic cancers (5–11). However, 
none of the clinically used nanotherapeutics (e.g., Onivyde and 
Abraxane) are tumor specific. These drugs depend solely on the 
enhanced permeability and retention effect to enter the tumor, which 
can be severely hindered by tumor complexity and heterogeneity 
(12). To overcome this obstacle, “next-generation” nanotherapeutics 
(e.g., MM302) use tumor-targeting ligands to improve their tumor 
accumulation. Unfortunately, these therapeutics failed to meet thera-
peutic expectations in clinical trials due to their limited targeting 
activity and “off-target” effects (13). Recent extensive studies of 
extracellular vesicles (e.g., exosomes) have shed light on the bio-
mechanisms of naturally occurring drug delivery nanocarriers 
(14–16). For instance, tumor-derived exosomes use multivalent 
ligand- receptor interactions between vesicles and targeted cells to 
mediate intercellular communication and efficiently deliver secreted 
proteins, mRNAs, and DNAs (15, 17, 18). Cells use a complex array 
of molecular interactions to deliver molecules that, in turn, govern 
cell functions. Multivalent targeting has been successfully achieved 
in nanomedicines by using two or more targeting ligands and effec-
tively enhances the delivery of nanomedicines to cancer cells in vitro 
and in vivo (19–28). A recent study has extended this strategy to 
simultaneously target tumor cells and their microenvironment, which 
significantly improved the antitumor activity of checkpoint blockade 
immunotherapy (21).
We have developed a complementary targeting strategy that im-
parts precisely matched, multivalent ligand-receptor interactions to 
efficiently enhance the retention of nanomedicines at targeted TNBC 
tumors and metastases. Unlike conventional targeted drug delivery 
systems that present a single ligand, we functionalized the surface of 
a liposome to precisely complement the molecular ratio and organi-
zation of multiple cancer receptors overexpressed on TNBC cell mem-
branes. We hypothesized that this precisely matched, multivalent 
ligand-receptor interaction between complementary targeting drug 
delivery systems and TNBC cells would increase cellular adhesion 
and accumulation at TNBC tumors and metastases in vivo, which, in 
turn, would improve the therapeutic efficacy of nanotherapeutics.
To test our hypothesis, we first developed an unbiased and quanti-
tative screening approach to select optimal targets for complementary 
targeting. On the basis of the screening data, we then engineered a 
proof-of-principle, dual complementary liposome (DCL) composed 
of antibodies against intercellular adhesion molecule–1 (ICAM1) 
and epithelial growth factor receptor (EGFR) (29, 30), which are 
molecular targets of U.S. Food and Drug Administration (FDA)–
approved drugs, and liposomal doxorubicin, a clinically used breast 
cancer nanotherapeutic (31). Our in vitro mechanistic studies fur-
ther revealed that DCLs exhibited three major advantages over con-
ventional “single” and “dual-targeting” liposomes: (i) Cellular binding 
was significantly increased via precisely matched, multivalent ligand- 
receptor interactions, (ii) internalization was enhanced via coopera-
tive endocytosis pathways, and (iii) therapeutic efficacy was improved 
1Vascular Biology Program, Boston Children’s Hospital, 300 Longwood Avenue, Boston, 
MA 02115, USA. 2Department of Surgery, Harvard Medical School and Boston Children’s 
Hospital, 300 Longwood Avenue, Boston, MA 02115, USA. 3Department of Biomed-
ical Engineering, The City College of New York, 160 Convent Avenue, New York, NY 
10031, USA.
*These authors contributed equally to this work as co-first authors.
†Present address: Department of Comparative Pathobiology, College of Veterinary 
Medicine, Purdue University, West Lafayette, IN 47907, USA.
‡Present address: Department of Chemical Engineering, Northeastern University, 
360 Huntington Avenue, Boston, MA 02115, USA.
§These authors contributed equally to this work as co-last authors.
‖Corresponding author. Email: d.auguste@northeastern.edu (D.T.A.); marsha.moses@
childrens.harvard.edu (M.A.M.)
Copyright © 2019 




for the Advancement 
of Science. No claim to 
original U.S. Government 
Works. Distributed 
under a Creative 
Commons Attribution 
License 4.0 (CC BY).
Guo et al., Sci. Adv. 2019; 5 : eaav5010     20 March 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
2 of 14
via simultaneous blockade of ICAM1 and EGFR pathways. Last, using 
in vivo orthotopic tumor and lung metastasis models, we demonstrated 
that potent tumor-targeting and antitumor activities of DCLs can be 
effectively translated into therapeutic and survival benefits by inhib-
iting TNBC tumor progression and metastasis. Together, these data 
demonstrate that complementary targeting is a promising and trans-
lational platform for the design of tumor-targeting nanomedicines.
RESULTS AND DISCUSSION
Selection of TNBC targets for complementary targeting
Multivalent binding is a proven method to increase selectivity and 
adhesion strength (19–28), yet no criteria for the rational selection of 
targets are described. To address this issue, we designed an unbiased 
and quantitative method to select and identify optimal target com-
binations for complementary targeting that could be generally ap-
plicable to many cancer types or diseases. Because complementary 
targeting relies on precisely matched multivalent ligand-receptor 
interaction, it is crucial to identify two highly overexpressed antigens 
as target combination and quantify their cell surface density and ratio. 
Although a number of TNBC targets (e.g., ICAM1, EGFR, CD44, 
etc.) have been previously identified (9, 32–35), their overexpression 
levels have not been systematically compared and their cell surface 
ratios are still unknown. We first screened human TNBC cells against 
a panel of 68 common cancer targets using comparative flow cyto-
metric analyses. In Fig. 1A, fig. S1, and table S1, we quantified the 
surface protein expression of these cancer targets in three human 
TNBC cell lines (MDA-MB-231, MDA-MB-436, and MDA-MB-157) 
in comparison with normal human mammary epithelial MCF10A 
cells. Of the 68 screened targets, 16 candidates were found to be 
Fig. 1. Identification of ICAM1 and EGFR as candidates for TNBC complementary targeting. (A) Surface protein expression of 68 cancer targets in three human TNBC 
cell lines and non-neoplastic MCF10A cells. Red and green bars represent maximum and minimum expression, respectively. High-magnification version is shown in fig. S1. 
(B) Venn diagrams summarize the cancer targets identified by flow cytometric analysis. Each circle represents the number of cancer targets up-regulated in one human 
TNBC cell line compared to non-neoplastic MCF10A cells. Overlapping sets show the differential expression in two or three comparison pairs, and 16 cancer targets were 
identified as up-regulated in all three TNBC cell lines compared to MCF10A cells. (C) Quantified surface densities of 16 target candidates. Red bars represent the five top 
candidates that were overexpressed in TNBC cells. (D) ICAM1 and EGFR gene expression in human TNBC and MCF10A cells as quantified by qRT-PCR. Significance was 
measured by one-way analysis of variance (ANOVA) with Bonferroni post hoc test. ***P < 0.001. (E) Representative microscopic images of immunofluorescent staining of 
ICAM1 and EGFR in three human TNBC cell lines and MCF10A cells. Scale bars, 5 m. DAPI, 4′,6-diamidino-2-phenylindol; FITC, fluorescein isothiocyanate; PE, phycoerythrin. 
(F) FRET analysis of ICAM1 and EGFR colocalization. Significance was measured by one-way ANOVA with Bonferroni post hoc test. FIU, fluorescence intensity unit; NS, not 
significant; **P < 0.01. (G) Correlation between overall survival and ICAM1/EGFR mRNA expression levels in patients with basal-like breast cancer, as shown with Kaplan-Meier 
analysis (*P < 0.05, log-rank test). Ab, antibody.
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commonly overexpressed in all three TNBC cell lines and were 
selected for further evaluation (Fig. 1B). As shown in Fig. 1C, ALCAM 
(activated leukocyte cell adhesion molecule), ITGA3 (integrin, alpha3), 
EGFR, ICAM1, and TFRC (transferrin receptor)  emerged as the most 
overexpressed TNBC targets relative to immunoglobulin G (IgG) 
controls among the 16 candidates. However, ALCAM, ITGA3, and 
TFRC were also found to be highly expressed in normal MCF10A 
cells which, if targeted, may cause off-target effects in normal mam-
mary tissues (Fig. 1C). For these reasons, we excluded ALCAM, 
ITGA3, and TFRC and selected ICAM1 and EGFR as the optimal 
targets for TNBC complementary targeting due to their high expres-
sion in TNBC cells and very low expression in normal cells relative 
to the other candidates. We recently reported ICAM1 as a novel 
TNBC target (8, 9); EGFR was also studied as a therapeutic target 
for TNBC (32–34). Both ICAM1 and EGFR are molecular targets 
for FDA-approved drugs (36, 37). However, to date, ICAM1 and EGFR 
have not been investigated as a target combination for TNBC- specific 
drug delivery.
We next measured the molecular ratio and organization of 
ICAM1 and EGFR on TNBC cell surfaces. As shown in table S2, we 
quantified the surface protein densities of ICAM1 and EGFR on 
TNBC cells and normal mammary epithelial cells. We also validated 
the overexpression of ICAM1 and EGFR in TNBC cells at the gene 
expression level using quantitative real-time polymerase chain reac-
tion (qRT-PCR) (Fig. 1D). Results were consistent with their pro-
tein levels on both TNBC and normal cells. We calculated the 
ICAM1/EGFR surface density ratio for each type of TNBC cell: 4.2:1 
for MDA-MB-231, 1.5:1 for MDA-MB-436, and 1.8:1 for MDA-
MB-157 (table S2). We selected MDA-MB-231 and MDA-MB-436 
for further investigation, as they exhibited the highest and lowest 
ratio of ICAM1/EGFR. These ICAM1/EGFR surface densities and 
molecular ratios represent critical design parameters for engineering 
TNBC-specific DCLs, given that they are the basis for determining 
the amount and ratio of ICAM1 and EGFR antibodies to be conjugated 
on the surface of DCLs. This, in turn, facilitates precisely matched, 
multivalent ligand-receptor interactions with TNBC cells.
Notably, immunofluorescent staining of ICAM1 and EGFR on 
TNBC cells revealed the overlapped staining of ICAM1 and EGFR 
(merged fluorescent images in Fig. 1E), indicating that ICAM1 and 
EGFR are colocalized in close spatial proximity on the cell mem-
brane. The colocalization of two receptors is a key design parameter 
in engineering of DCLs because complementary targeting requires 
ICAM1 and EGFR antibodies on the DCL surface to be in contact 
with both target receptors on the TNBC cell membrane at the same 
time. Therefore, ICAM1 and EGFR must spatially reside within the 
distance of the DCL diameter (approximately 130 nm). The colocal-
ization of ICAM1 and EGFR on TNBC cells was also confirmed using 
a fluorescence resonance energy transfer (FRET) assay. As demon-
strated in Fig. 1F, MDA-MB-231, MDA-MB-436, and MCF10A cells 
were costained with Alexa Fluor 488–ICAM1 antibody (FRET donor: 
excitation, 495 nm; emission, 515 nm) and Alexa Fluor 555–EGFR 
antibody (FRET receptor: excitation, 519 nm; emission, 565 nm). FRET 
signals from the donor-receptor pair were observed on both TNBC 
cells but were absent in normal MCF10A cells, indicating that ICAM1 
and EGFR are present within the Förster radius of 10 nm [the maxi-
mum distance for FRET events (38)] on TNBC cell membranes.
We also analyzed the potential impact of ICAM1 and EGFR over-
expression on the overall survival of patients with basal-like breast 
cancer (majority are TNBC cases) in a cohort of 25 specimens using 
the R2: Genomics Analysis and Visualization Platform (https://hgserver1.
amc.nl/; Datasheet: Tumor Breast - Bergh - 159 - MAS5.0 - u133a) (39). 
Basal-like breast cancer patients with high expression of both ICAM1 
and EGFR demonstrated the worst prognosis (P = 0.023, log-rank test; 
Fig. 1G) relative to overexpression of ICAM1 and EGFR alone. These 
findings suggest that high expression of ICAM1 in combination with 
high expression of EGFR may serve as an important clinical biomarker 
of poor prognosis in patients with basal-like breast cancer.
Although many cell membrane proteins (e.g., ICAM1, EGFR, and 
CD44) identified from our surface marker screening have previously 
been reported as promising TNBC targets (9, 32–35), the novelty of 
this surface marker screening study lies in identifying the optimal 
cancer target combination for dual complementary targeting, which 
requires a quantitative and systematic comparison of current TNBC 
antigens. The optimal antigens need to be highly overexpressed and 
colocalized within the same cell membrane regions of TNBC cells 
while having minimum expression on normal cells. The quantitative 
molecular ratio of the dual target combination is also critical for me-
diating successful dual complementary targeting. Such information 
has not yet been quantified until this current study.
Engineering complementary targeting liposomes (DCLs)
Nontargeting liposomal doxorubicin (e.g., Doxil and Myocet) is FDA- 
approved; these breast cancer nanomedicines exhibit fewer adverse 
effects and better safety profiles than conventional chemotherapeutics 
(31, 40, 41). Unfortunately, these nontargeting liposomes fail to exhibit 
significantly improved clinical benefits against TNBC due to their 
limited tumor delivery (40–42). We reasoned, therefore, that combin-
ing our novel complementary targeting strategy with clinically used 
liposomal doxorubicin would enable a nanotherapeutic to specifically 
recognize and target TNBC tumors and spare healthy organs and tis-
sues. This approach increases the drug delivery to, and dosage in, tu-
mors, reduces nonspecific uptake, and attenuates adverse effects.
To test our hypothesis, we designed a proof-of-principle DCL 
by covalently conjugating both ICAM1- and EGFR-neutralizing 
antibodies on the surface of liposomal doxorubicin at optimal anti-
body ratios for different types of TNBC cells (Fig. 2A). For exam-
ple, 4.2:1 (ICAM1/EGFR antibody) for MDA-MB-231 and 1.5:1 
for MDA-MB-436 cells. DCLs were composed of 1,2-dioleoyl- sn-
glycero-3- phosphocholine (DOPC) and 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N- [carboxy(polyethylene glycol)-2000] 
(DSPE-PEG-COOH) (95/5, mol/mol). We characterized the size 
and monodispersity of synthesized DCLs by dynamic light scattering 
measurements (table S3 and fig. S2). All DCLs and control liposomes 
exhibited uniform hydrodynamic radii of approximately 130 ± 30 nm 
and z potentials between −6 and −10 mV. The ICAM1/EGFR anti-
body ratios conjugated on DCL surfaces were also measured and are 
close to their theoretical values (table S4).
Complementary targeting enhances liposome binding to 
TNBC cells
TNBC binding and uptake of DCLs were determined by both flow 
cytometry and immunofluorescent staining. As demonstrated in 
Fig. 3A, we treated MDA-MB-231 and MDA-MB-436 cells with 
fluorescein isothiocyanate (FITC)–labeled DCLs with different 
ICAM1/EGFR antibody ratios (DCL-FITC_4.2/1, _1.5/1, and _1/1), 
FITC-labeled ICAM1 or EGFR single-targeting liposomes (ICAM-
FITC-LP or EGFR-FITC-LP), or nontargeting IgG-FITC-LP in the 
presence of serum [10% fetal bovine serum (FBS)]. DCL-FITC_4.2:1 
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(ICAM1/EGFR antibody ratio 4.2/1, optimized for MDA-MB-
231cells) exhibited a 4.7-fold increase in binding with MDA-
MB-231 cells as compared to IgG-FITC-LP, significantly higher 
than other tested DCLs and ICAM1 or EGFR single- targeting lipo-
somes. Consistently, DCL-FITC_1.5/1 (ICAM1/EGFR antibody 
ratio 1.5/1, optimized for MDA-MB-436 cells) exhibited the highest 
cellular binding with MDA-MB-436 cells (Fig. 3A). Meanwhile, we 
observed no obvious changes in cellular binding in normal MCF10A 
cells treated with DCLs or control liposomes due to their lack of 
either ICAM1 or EGFR expression. We also observed increased 
cellular binding with DCL-FITC with immunofluorescent staining 
(Fig. 3B). These results demonstrated that the ICAM1/EGFR anti-
body ratio plays a critical role in regulating multivalent ligand- 
receptor interactions between DCLs and TNBC cells. As illustrated 
in Fig. 2B, only when the ICAM1/EGFR antibody ratio on DCLs 
precisely complements the ICAM1/EGFR expression ratio on 
TNBC cells does the multivalent ligand-receptor interaction reach 
its maximum efficiency and generate the strongest cooperative 
adhesion specifically toward TNBC cells, thereby significantly pro-
moting TNBC cellular binding.
We also treated cells with single-targeting liposomes mixed at 
different ratios. It is important to note that simply mixing ICAM1 
and EGFR single-targeting liposomes at matching molar ratios 
(e.g., 4.2/1, 1.5/1, and 1/1) did not improve their cellular binding 
in comparison with DCLs (Fig. 3A). This is due to the fact that the 
mixture of single- targeting liposomes alone lacks the multivalent 
ligand-receptor interaction toward TNBC cells and also causes 
steric hindrance as both ICAM-FITC-LP and EGFR-FITC-LP 
compete to bind colocalized ICAM1 and EGFR in the same cell 
surface regions.
Complementary targeting significantly enhances liposome 
internalization in TNBC cells
The advantages of complementary targeting are not limited to 
the increased TNBC cellular binding. We also observed that this 
strategy substantially enhanced TNBC cell internalization of lipo-
somes via cooperative endocytosis pathways (Fig. 2C). It is known 
that EGFR internalization mainly depends on clathrin-mediated 
endocytosis (43), while ICAM1 internalization relies on an alterna-
tive cell adhesion molecule (CAM)–mediated pathway (44). We 
reasoned that DCLs may simultaneously bind and activate both 
ICAM1 and EGFR internalization pathways and enter TNBC cells 
via a synergy of clathrin- and CAM-mediated endocytosis. To test 
this hypothesis, we performed trypan blue quenching assays on 
DCL-FITC–treated TNBC cells to block the extracellular fluores-
cence from bound and non-internalized DCL-FITCs and calculated 
the internalization ratio of DCL-FITCs by dividing the cellular flu-
orescence of internalized DCL-FITCs by the total cellular fluores-
cence composed of both extracellular and internalized DCL-FITCs 
(Fig. 3C). Unexpectedly, ICAM1- or EGFR single- targeting lipo-
somes, which exhibited increased cellular binding (Fig. 3, A and B), 
bound to TNBC cell surfaces via ICAM1 or EGFR antibody- antigen 
interactions and were not effectively internalized by TNBC cells. 
This may be due to the limited efficacy of the ICAM1 or EGFR 
single endocytosis pathway. In contrast, DCL-FITCs significantly 
restored the internalization ratio back to 42.7% for MDA-MB-231 
cells and 60.9% for MDA-MB-436 cells while maintaining their 
highly specific TNBC cellular binding (Fig. 3C). The IgG group 
demonstrated a high internalization ratio (40 to 60%) due to its low 
affinity for the cell surface compared to other groups. These results 
demonstrated that the complementary targeting strategy enables 
Fig. 2. Schematic illustration of DCL structure and biomechanisms of complementary targeting strategy. (A) The design of the proof-of-principle binary DCL for 
TNBC. (B) DCL increases cellular binding using precisely matched, multivalent ligand-receptor interactions. (C) DCL enhances internalization using cooperative ICAM1 and 
EGFR endocytosis pathways. (D) DCL improves therapeutic efficacy using synergistic blockade of ICAM1 and EGFR signaling cascades.
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liposomes to enter TNBC cells more efficiently via cooperative 
endocytosis pathways. Naturally occurring proteins [e.g., LRP1 
(low density lipoprotein receptor-related protein 1)] are known to 
harness these cooperative endocytosis pathways to enhance their 
cell entry (45, 46).
We hypothesize that synthetic nanocarriers can exploit multiple 
endocytosis pathways to improve cell internalization. The detailed 
biomechanism(s) of this synergy between clathrin and CAM-mediated 
endocytosis pathways merits further investigation.
Complementary targeting cooperatively blocks ICAM1 and 
EGFR signaling cascades
We engineered our DCLs with ICAM1- and EGFR-neutralizing anti-
bodies that could simultaneously block ICAM1 and EGFR signaling 
Fig. 3. DCL increases in vitro TNBC targeting and antitumor activities. (A) In vitro cellular binding and uptake of DCL-FITC and controls in human TNBC and MCF10A 
cells were determined by flow cytometry in reference to IgG-FITC-LP. (B) Representative fluorescent images showing TNBC-specific cellular binding and uptake of 
DCL-FITCs in TNBC cells in comparison with IgG-FITC-LP, ICAM-FITC-LP, and EGFR-FITC-LP. Scale bars, 20 m. (C) Internalization ratios of DCL-FITC and controls were de-
termined by a trypan blue (TB) quenching assay. Black bars (without trypan blue quenching) represent total cellular fluorescence from both extracellular and internalized 
liposomes, and gray bars (with trypan blue quenching) represent cellular fluorescence from internalized liposomes only. (D) Quantified analysis of therapeutic efficacies 
of DCL (vehicle without Dox) and controls on TNBC cell proliferation. Representative microscope images (E) and quantitative analysis (F) of invaded TNBC cells in a tran-
swell invasion assay. Scale bars, 50 m. (G) In vitro cytotoxicity of DCL-Dox was evaluated for MDA-MB-231 and MDA-MB-436 cells by Dojindo cell viability assay in refer-
ence to DCL (vehicle without Dox). Significance was measured by one-way ANOVA with Bonferroni post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001.
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cascades in TNBC cells (Fig. 2D). The EGFR-neutralizing antibody 
cetuximab is an FDA-approved antitumor agent for treating a variety 
of metastatic tumors (47). ICAM1-neutralizing antibodies, enlimomab 
and BI-505, have shown promising antitumor activities against many 
cancers (30, 48, 49). We therefore reasoned that our DCL is not only 
a drug delivery nanocarrier but also a TNBC-targeted therapeutic 
agent that synergistically inhibits both ICAM1 and EGFR pathways 
in TNBC cells and therefore blocks multiple processes during cancer 
progression. We therefore investigated the impact of the DCL vehi-
cle (without Dox) on both TNBC cell proliferation and invasion. 
DCLs exhibited a 30 to 40% inhibitory effect on TNBC cell prolifera-
tion in vitro in both MDA-MB-231 and MDA-MB-436 cells (Fig. 3D). 
Moreover, as presented in Fig. 3 (E and F), DCLs exhibited potent 
inhibitory activity against TNBC cell invasion. The number of invaded 
MDA-MB-231 and MDA-MB-436 cells was significantly reduced 
by 64 and 46%, respectively, by DCL treatment in comparison with 
phosphate-buffered saline (PBS) controls. Notably, we observed a 
similar inhibitory effect with ICAM-LP but not with EGFR-LP, in-
dicating that the inhibitory function of DCLs against cell invasion may 
be attributed to the blockade of the ICAM1 pathway rather than the 
EGFR pathway. This inhibitory effect was consistent with previous 
studies using free ICAM1-neutralizing antibodies (49). On the basis 
of these data, we postulated that ICAM1-neutralizing antibodies of 
DCLs may work as bioactive therapeutic agents against TNBC pro-
gression and metastasis via blocking its pathway.
The potent inhibitory effects of this DCL vehicle on TNBC cell 
proliferation and invasion may further synergize with its chemo-
therapeutic payloads (e.g., doxorubicin) to generate maximal thera-
peutic benefits in vivo against TNBC progression and metastasis. 
To test this hypothesis, we loaded DCLs with doxorubicin (DCL-Dox), 
a commonly used breast cancer chemotherapy drug, and evaluated 
its half maximal inhibitory concentration (IC50) in two human 
TNBC cell lines. Doxorubicin-loaded DCL_4.2/1 (DCL-Dox_4.2/1) 
(optimized for MDA-MB-231 cells) showed significantly improved 
cytotoxicity against MDA-MB-231 cells, 13-fold higher than the 
cytotoxicity from IgG-conjugated PEGylated liposomal doxorubicin 
(IgG-Dox-LP) (Fig. 3G). The quantified IC50 for IgG-Dox-LP, 
ICAM-Dox-LP, EGFR-Dox-LP, and DCL- Dox_4.2/1 in MDA-
MB-231 cells were 11.7, 2.4, 4.8, and 0.9 g/ml, respectively. We 
also observed a 1MDA-MB-436 cells, achieving the lowest IC50 
of DCL-Dox_1.5/1 (0.04 g/ml) compared with IgG-Dox-LP 
(3.74 g/ml), ICAM-Dox-LP (0.08 g/ml), and EGFR-Dox-LP 
(0.23 g/ml). In summary, DCL-Dox exhibited the lowest IC50 in 
both MDA-MB-231 and MDA-MB-436 cells due to their comple-
mentary targeting capability.
DCL inhibits orthotopic TNBC tumor growth and metastasis
We first evaluated the in vivo tumor-targeting activity of DCLs using 
near-infrared (NIR) fluorescent imaging in an orthotopic TNBC tu-
mor model (Fig. 4A). We labeled DCL_4.2/1 with 1,1′-dioctadecyl- 
3,3,3′,3′-tetramethylindotricarbocyanine iodide (DiR), a NIR lipid dye, 
(DCL-DiR_4.2/1) and intravenously injected it into luciferase-labeled 
MDA-MB-231 (MDA-MB-231-Luc) tumor–bearing mice. We used 
IgG-DiR-LP, ICAM-DiR-LP, and EGFR-DiR-LP as controls. We 
performed in vivo NIR imaging at 6, 24, and 48 hours after injection. 
Among four tested formulations, the DCL-DiR_4.2/1 group demon-
strated the highest tumor accumulation at all time points (Fig. 4B). 
Quantified NIR signals confirmed that the tumor accumulation 
of DCL-DiR_4.2/1 was 2.8-fold higher than that of IgG-DiR-LP at 
24 hours after a single tail vein administration. We quantified the 
tumor accumulation percentage of DCL-DiR_4.2/1 by dividing the 
tumor NIR signal (the NIR signal integrated over the tumor area) by 
the total NIR signal of administered DiR-labeled liposomes. We quan-
tified the average percentage of DCL-DiR_4.2/1 accumulated in the 
tumors as 3.3% in comparison with 1.2% of IgG- DiR-LP, 2.0% of 
ICAM-DiR-LP, and 1.3% EGFR-DiR-LP (Fig. 4C). We evaluated 
the biodistribution of DCL-DiR_4.2/1 using ex vivo quantification 
of NIR signals in six organs and tumors excised from mice at 48 hours 
(Fig. 4, D and E). Correlating with in vivo whole mouse imaging 
data, DCL-DiR_4.2/1 accumulated in excised tumors approximately 
1.7-fold higher than that of IgG-DiR-LP (Fig. 4E). These results 
demonstrated that complementary targeting is more effective than 
conventional single-targeting approaches in recognizing and targeting 
TNBC tumors in vivo.
The dual-targeting strategy is known to enhance tumor uptake of 
nanomedicines (22–28); however, the impact(s) of optimizing the 
targeting ligand ratio on in vivo delivery efficacy is still unclear, and, 
to date, the target ligand ratio is not used as a design parameter for 
dual-targeted nanomedicines. Thus, we systematically compared the 
in vivo tumor uptake of DCLs with three distinct ICAM1/EGFR anti-
body ratios (4.2/1, 1/1, 1/4.2, mol/mol) in an orthotopic TNBC model 
(MDA-MB-231-Luc) as described above. A mixture of two single- 
targeting liposomes (ICAM-DiR-LP and EGFR-DiR-LP, 1/1, mol/
mol) and nonspecific IgG-DiR-LP were used as controls. As shown 
in Fig. 4 (F and G), DCL-DiR_4.2/1, with the precise ICAM1/EGFR 
antibody ratio to complement the antigen overexpression in MDA-
MB-231-Luc tumors, exhibited over 2.5-fold increased tumor up-
take than IgG-DiR-LP, significantly higher than other DCLs with 
equivalent and reversed antibody ratios (1.6-fold for DCL-DiR_1/1 
and 1.2-fold for DCL-DiR_1/4.2). This in vivo tumor uptake of 
DCL-DiR_4.2/1 was also found being consistent with previous bio-
distribution studies (Fig. 4C). The mixture of ICAM-DiR-LP and 
EGFR-DiR-LP did not effectively improve the in vivo tumor uptake 
due to their lack of multivalent ligand-receptor interactions. To our 
knowledge, the in vivo data presented here are the first experimental 
evidence of targeting ligand ratio regulating in vivo tumor uptake 
for “dual-ligand targeting” nanomedicines.
We next examined the therapeutic efficacy of DCL-Dox_4.2/1 in 
inhibiting orthotopic TNBC tumor growth and metastasis (Fig. 4H). 
Doxil (PEGylated liposomal doxorubicin) is an FDA-approved 
nanomedicine but failed to demonstrate enough therapeutic efficacy 
against TNBC (31, 40). We hypothesized that combining our com-
plementary targeting with clinically used Doxil could increase drug 
delivery to TNBC tumors and improve therapeutic efficacy. To 
evaluate the effectiveness of this complementary targeting strategy, 
we chose to use nontargeting IgG-Dox-LP as a surrogate of Doxil 
to compare with DCL-Dox_4.2/1 because these formulations share 
the same physiochemical properties except their targeting activity. 
MDA-MB-231-Luc tumor–bearing mice were randomly divided 
into six groups and received treatment of PBS (sham), free doxo-
rubicin (free Dox), IgG-Dox-LP, ICAM-Dox-LP, EGFR-Dox-LP, 
or DCL-Dox_4.2/1, respectively, at a Dox dosage of 2.5 mg/kg via 
retro- orbital injection. As shown in Fig. 4 (I and J), after a 21-day 
treatment regimen, DCL-Dox_4.2/1 exhibited the highest inhibitory 
effect on TNBC tumor growth among all tested groups. The quanti-
fied tumor mass revealed that DCL-Dox significantly reduced TNBC 
tumor growth by 70.3%, approximately threefold more efficient 
than IgG-Dox-LP (Fig. 4K). Furthermore, as shown in Table 1, 
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DCL-Dox_4.2/1 substantially inhibited spontaneous metastasis com-
pared to other groups (1 of 10 mice versus 5 of 9 to 8 of 8 mice). 
Overall, DCL-Dox_4.2/1 exhibited significantly higher biodistribu-
tion in the tumor, lower tumor growth, and inhibited metastasis 
relative to all controls.
DCL inhibits TNBC lung metastasis
To extend the application of complementary targeting strategy to 
metastatic TNBC, we examined the antitumor activity of DCL-Dox 
in a lung metastasis model, which is known to be more aggressive and 
more refractory to conventional chemotherapy than an orthotopic 
Fig. 4. DCL-Dox inhibits orthotopic tumor growth and metastasis. (A) Schematic design of orthotopic tumor biodistribution imaging. (B) In vivo NIR fluorescent 
images of nude mice at 4, 24, and 48 hours after the administration of IgG-DiR-LP, ICAM-DiR-LP, EGFR-DiR-LP, and DCL-DiR_4.2/1. n = 8 per group. (C) Quantitative analysis 
of in vivo tumor accumulation of DCL-DiR_4.2/1 and control liposomes. (D) Representative ex vivo NIR fluorescent images of organs (liver, spleen, kidney, lung, heart, and 
brain) and excised tumors. (E) Biodistribution of administrated agents in different organs and tumors after 48 hours. (F) TNBC tumor specificity of DCLs with three distinct 
ratios (4.2/1, 1/1, and 1/4.2, mol/mol) and a mixture of two single-targeting liposomes (ICAM-DiR-LP and EGFR-DiR-LP, 1/1, mol/mol) in the orthotopic TNBC model (MDA-
MB-231) (n = 5 per group). (G) Tumor accumulation of liposomes was determined at 48 hours after injection by NIR fluorescent intensity (n = 5 per group). (H) Schematic 
design of orthotopic tumor therapy model. (I) Image of excised orthotopic TNBC tumors from mice treated with PBS (sham), free Dox, IgG-Dox-LP, ICAM-Dox-LP, EGFR-
Dox-LP, or DCL-Dox_4.2/1 under a 21-day treatment regimen (n = 7 to 10 per group). (J) Tumor progression was closely monitored by weekly tumor volume measurement 
using caliper. (K) Tumor mass at end point (day 24) was quantified in weight. Significance was measured by one-way ANOVA (C, E, G, and K) or two-way ANOVA (J) with 
Bonferroni post hoc test. *P < 0.05; **P < 0.01; ***P < 0.001.
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tumor model (50–53). We generated TNBC lung metastases by 
tail vein administration of MDA-MB- 231-Luc cells (Fig. 5A). After 
confirming the formation of lung metastasis by in vivo biolumines-
cence imaging (Fig. 5B), mice were randomly divided into the same 
treatment groups used in the orthotopic model and administered 
via retro-orbital injection. After a 21-day treatment regimen, lung 
metastasis in each group was closely monitored by weekly bio-
luminescence imaging up to 124 days (Fig. 5, B and C). As shown in 
Fig. 5 (B and C), DCL-Dox completely inhibited the progression of 
TNBC lung metastasis compared to the other groups. None of the 
mice treated with DCL-Dox_4.2/1 developed lung metastases, whereas 
six of eight mice in the nontargeting IgG-Dox-LP and EGFR-Dox-LP 
group developed metastases (Table 1). ICAM- Dox-LPs also exhibited 
a slightly lower inhibitory activity (two of eight mice) than DCL-Dox, 
which correlates with the in vitro cell invasion studies (Fig. 3H). The 
DCL-Dox_4.2/1 complete inhibition of TNBC metastasis formation 
on excised lungs was confirmed in Fig. 5 (D and E). We further found 
that this potent metastasis inhibitory activity of DCL-Dox_4.2/1 led 
to significant survival benefits. As shown in Fig. 5F, DCL-Dox sub-
stantially improved metastasis-free survival in comparison with all 
groups except ICAM-Dox-LP.
Determination of the optimal dosage for DCL therapy
We further performed a dosage-dependent study to determine 
the minimum effective dosage of DCL-Dox treatment (Fig. 5G). 
Mice with MDA-MB-231 lung metastases were treated with PBS 
(sham) or DCL-Dox_4.2/1 at three dosages (0.625, 1.25, and 2.5 
Dox mg/kg) for up to 75 days. DCL-Dox at the dosages of 0.625 and 
1.25 mg/kg did not inhibit lung metastasis as effectively as DCL-
Dox at the dosage of 2.5 mg/kg (Fig. 5, H and I). Kaplan-Meier sur-
vival analysis further confirmed the significantly increased survival 
benefit of the 2.5 mg/kg dosage compared to the lower dosages 
(Fig. 5J). Thus, DCL-Dox_4.2/1 at the dosage of 2.5 mg/kg Dox 
was considered to be the optimal dosage for treating metastatic 
MDA-MB-231 tumors.
We evaluated the chronic liver and renal toxicity of DCL-Dox_4.2/1 
treatment via blood chemistry analysis. At the end of the DCL-
Dox_4.2/1 dosage-dependent study (day 75), we collected the serum 
from each dosage group and measured aspartate aminotransferase 
(AST) and alanine aminotransferase (ALT) levels to evaluate liver tox-
icity. As shown in Fig. 5K, among all DCL-Dox_4.2/1 dosages, none 
of them, including the highest one, induced any elevation in either 
AST or ALT levels compared with the PBS group. Similarly, we eval-
uated the renal toxicity of DCL-Dox_4.2/1 by measuring creatinine 
and blood urea nitrogen (BUN) levels, and we observed no renal 
toxicity among these DCL-Dox_4.2/1 dosage groups (Fig. 5K). The 
highest Dox dosage at 2.5 mg/kg for 75 days in mice is equivalent to 
a Dox cumulative dosage of 1760 mg/m2 in human, which is close to 
the Dox life time cumulative dosage of 2220 mg/m2 in human (54). 
These in vivo data demonstrate that DCL-Dox_4.2/1 at 2.5 mg/kg 
dosage exhibited the highest inhibitory activity against primary and 
metastatic TNBC tumors while exhibiting no systemic toxicity.
In summary, we have demonstrated that complementary targeting 
is a highly precise and effective strategy to recognize and target TNBC 
tumors both in vitro and in vivo. We have engineered a dual comple-
mentary targeting, Dox-encapsulating liposome that significantly 
inhibits TNBC tumor progression and metastasis in both orthotopic 
tumor and lung metastasis models. In addition, we have provided an 
unbiased and quantitative screening method to identify optimal candi-
dates for dual-targeted drug delivery, which provides the opportunity 
Table 1. Summary of metastasis formation in TNBC orthotopic and lung metastasis models.  
Metastatic site PBS (sham) Free Dox IgG-Dox-LP ICAM-Dox-LP EGFR-Dox-LP DCL-Dox_4.2/1
Orthotopic breast tumor model
Brain 0/8 0/8 0/7 0/9 0/8 0/10
Lung 1/8 0/8 0/7 0/9 1/8 0/10
Heart 0/8 0/8 0/7 0/9 0/8 0/10
Liver 3/8 0/8 2/7 0/9 1/8 0/10
Spleen 3/8 0/8 2/7 1/9 1/8 1/10
Kidney 0/8 0/8 0/7 0/9 0/8 0/10
Right hind limb 
(tumor bearing) 6/8 8/8 5/7 4/9 5/8 1/10
Left hind (normal) 1/8 0/8 0/7 2/9 1/8 0/10
Total 7/8 8/8 6/7 5/9 5/8 1/10
Lung metastasis model
Brain 0/8 0/8 0/8 0/8 0/8 0/8
Lung 8/8 5/8 6/8 2/8 6/8 0/8
Heart 0/8 0/8 0/8 0/8 0/8 0/8
Liver 2/8 0/8 1/8 0/8 0/8 0/8
Spleen 1/8 0/8 0/8 0/8 0/8 0/8
Kidney 0/8 0/8 0/8 0/8 0/8 0/8
Hind limbs (normal) 0/8 0/8 0/8 0/8 0/8 0/8
Total 8/8 5/8 6/8 2/8 6/8 0/8
Guo et al., Sci. Adv. 2019; 5 : eaav5010     20 March 2019
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
9 of 14
for other investigators to readily apply this complementary targeting 
strategy to the design of nanomedicines to treat other cancers or 
diseases. We have elucidated the biomechanisms by which comple-
mentary targeted nanotherapeutics interact with biological systems, 
providing tunable parameters to optimize tumor specificity and thera-
peutic efficacy for multivalent nanomedicines.
MATERIALS AND METHODS
Materials
Dulbecco’s PBS, 4′,6-diamidino-2-phenylindole (DAPI), 0.25% 
trypsin/2.6 mM EDTA solution, Gibco Dulbecco’s modified Eagle’s 
medium (DMEM), Gibco DMEM/F12 (1:1), and Gibco 0.4% trypan 
blue solution were purchased from Invitrogen (Carlsbad, CA, USA). 
1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride 
(EDC), N-hydroxysuccinimide (NHS), bovine serum albumin (BSA), 
anhydrous dimethyl sulfoxide (DMSO), Dox, FITC -dextran [mo-
lecular weight (MW), 10 kDa], AST activity assay kit, ALT activity 
assay kit, creatinine activity assay kit, and urea activity assay kit 
were purchased from Sigma-Aldrich (St. Louis, MO, USA). Corning 
BioCoat Matrigel Invasion Chamber with BD Matrigel Matrix, 
Lab-Tek II Chamber Slide System, formaldehyde, chloroform, 
anhydrous ethanol (EtOH), Slide-A-Lyzer dialysis cassette [molecu-
lar weight cut-off (MWCO), 10 kDa], DiR, and Diff-Quik Stain Set 
Fig. 5. DCL-Dox inhibits TNBC lung metastasis and improves survival. (A) Schematic design of TNBC lung metastasis therapy. (B) Representative bioluminescence 
images of lung metastasis at different time points in mice treated with the following agents: PBS (sham), free Dox, IgG-Dox-LP, ICAM-Dox-LP, EGFR-Dox-LP, or DCL-
Dox_4.2/1 (n = 8 per group). (C) Representative tumor progression curves as depicted from in vivo bioluminescence signal intensity (n = 3 per group). (D) Size and 
morphology of lungs excised from mice in different treatment groups. (E) Quantification of metastasis node numbers on excised lungs from mice in different treatment 
groups. (F) Metastasis-free survival of mice in DCL-Dox and control groups as displayed by Kaplan-Meier curves (log-rank test).  (G) Schematic design for dosage-dependent 
therapy. iv, intravenous. (H) In vivo bioluminescence images of mice in the dosage-dependent study. Tumor-bearing mice were treated with DCL-Dox_4.2/1 at different 
dosages and imaged at day 74 or an earlier sacrifice date (n = 5 per group). “*” indicates the mouse sacrificed at day 22 due to blindness caused by retro-orbital injection). 
(I) Quantification of metastasis node numbers on excised lungs in the dosage-dependent study. (J) Metastasis-free survival of mice in the dosage- dependent study as 
displayed by Kaplan-Meier curves (log-rank test). (K) Serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, and blood urea nitrogen 
(BUN) (n = 4 to 5 per group). Significance was measured by one-way ANOVA with Bonferroni post hoc test (E, I, and K). *P < 0.05; **P < 0.01; ***P < 0.001.
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were purchased from Thermo Fisher Scientific (Pittsburgh, PA, USA). 
Mouse antihuman ICAM1-neutralizing antibody (clone BBIG-I1) 
and IgG isotype were purchased from R&D Systems (Minneapolis, 
MN, USA). Phycoerythrin (PE)–conjugated mouse/rat antihuman 
antibodies against 68 cancer target candidates (table S1), FITC-
ICAM1 antibody, Alexa Fluor 488–ICAM1 antibody, and FITC- and 
PE- conjugated mouse IgG isotypes were purchased from BioLegend 
(San Diego, CA, USA). Mouse antihuman EGFR- neutralizing anti-
body (clone LA1) and Alexa Fluor 555–EGFR antibody were 
purchased from EMD Millipore (Billerica, MA, USA). DOPC 
and DSPE-PEG-COOH were purchased from Avanti Polar Lipids 
(Alabaster, AL, USA). Quantum Simply Cellular microbeads were 
purchased from Bangs Laboratory (Fishers, IN, USA). Qiagen 
RNeasy Mini Kit was purchased from Qiagen (Germantown, MD, 
USA). FLOAT-A-LYZER G2 dialysis tubing (MWCO, 1000 kDa) 
was purchased from Spectrum Laboratories (Rancho Dominguez, 
CA, USA). Two-micrometer borosilicate beads were purchased from 
Thomas Scientific (Swedesboro, NJ, USA). Dojindo cell counting kit 
was purchased from Dojindo Molecular Technologies (Rockville, 
MD, USA). BD Vacutainer was purchased from Becton Dickinson 
(Franklin Lakes, NJ, USA).
Cell culture
Three human TNBC cell lines (MDA-MB-231, MDA-MB-436, 
and MDA-MB-157) and one human non-neoplastic mammary 
epithelial cell line (MCF10A) were used in the presented study. 
All four cell lines were purchased from American Type Culture 
Collection (Manassas, VA, USA). MDA-MB-231, MDA-MB-436, 
and MDA-MB-157 cells were cultured in DMEM, and MCF10A 
cells were cultured in DMEM/F12 (1:1), with all recommended 
supplements. All cells were maintained at 37°C in a humidified 
incubator with 5% CO2. Luciferase- labeled MDA-MB-231 (MDA-
MB-231-Luc-D3H2LN) cells were purchased from PerkinElmer 
(Hopkinton, MA, USA) and cultured using the same condition as 
MDA-MB-231 cells.
Screening and identification of optimal targets for  
complementary targeting
Cell membrane expression of molecular target candidates was eval-
uated using a BD FACSCalibur Flow Cytometer (BD Biosciences, 
San Jose, CA, USA), as described previously (7). Briefly, 106 cells were 
collected and rinsed twice through suspension-spin cycles. Cells were 
blocked by 1% BSA in PBS for 30 min in an ice bath. After BSA block-
ing, cells were incubated with PE-conjugated antibodies for 1 hour 
at room temperature (RT). Cells were rinsed twice with 1% BSA in 
PBS, resuspended in PBS, and evaluated by flow cytometry. Density 
of molecular targets on the cell surface was determined with refer-
ence to Quantum Simply Cellular microbeads, using the protocol 
provided by the manufacturer.
Quantification of gene expression
Gene expression levels of ICAM1 and EGFR in TNBC cells were 
characterized using qRT-PCR. Cells were cultured overnight at 
3 × 105 cells per well in a six-well cell culture plate. Cells were then 
removed from each well by incubating with a 0.25% trypsin/2.6 mM 
EDTA solution for 3 min. The cells were washed three times with 
PBS. RNA was extracted, purified using the Qiagen RNeasy Mini 
Kit, and quantified using a SpectraMaxPlus 384 UV-Visible Spectro-
photometer (Molecular Devices Corporation, Sunnyvale, CA, USA). 
Reverse transcription was conducted using the Applied Biosystems 
TaqMan RT protocol. Detection and quantification of mRNA were 
performed using the StepOnePlus Real-Time PCR System (Applied 
Biosystems, Carlsbad, CA, USA). All PCR samples were referenced 
to the gene expression level of glyceraldehyde 3-phosphate dehydro-
genase.
Immunofluorescent staining
Twenty thousand cells were seeded in a Lab-Tek II Chamber Slide 
System with 2-ml medium overnight at 37°C. After medium was re-
moved, cells were rinsed twice with PBS and fixed with 4% formal-
dehyde in PBS at RT for 10 min, followed by washing with PBS. 
Samples were blocked with 1% BSA in PBS for 30 min in an ice bath. 
After BSA blocking, samples were costained with FITC-conjugated 
ICAM1 antibody and PE-conjugated EGFR antibody for 1 hour and 
rinsed with PBS. DAPI was used to stain the cell nucleus. Immuno-
fluorescent stained samples were dried overnight in the dark and 
used for fluorescent microscope imaging. Samples were examined 
under a Leica TCS SP5 confocal fluorescent microscope (Leica Mi-
crosystems, Buffalo Grove, IL, USA).
FRET assay
The FRET assay was performed on live MDA-MB-231, MDA-
MB-436, and MCF10A cells. Cells (104) were seeded in each well of 
a 96-well plate and grown overnight. Cells were washed twice with 
PBS and incubated with PBS, Alexa Fluor 488–ICAM1 antibody 
(donor), Alexa Fluor 555–EGFR antibody (receptor), or a mixture 
of Alexa Fluor 488–ICAM1 antibody and Alexa Fluor 555–EGFR 
antibody (donor + receptor, 1:1) at a final antibody concentration 
of 1 g/106 cells for 45 min at 37°C. After staining, cells were washed 
twice with PBS, and their FRET signals were measured at the 
donor’s excitation wavelength of 495 nm and the receptor’s emis-
sion wavelength of 565 nm using a SpectraMaxPlus 384 UV- Visible 
Spectrophotometer (Molecular Devices Corporation, Sunnyvale, 
CA, USA).
Preparation of doxorubicin-encapsulating DCL (DCL-Dox)
DCL-Dox was prepared by the extrusion method as described pre-
viously with modifications (7, 8, 10, 11). Briefly, a lipid formulation 
consisted of DOPC:DSPE-PEG-COOH (95:5, mol/mol) was used to 
prepare liposomes. Lipid mixture (50 mol) was solubilized in chloro-
form and dried under a dry nitrogen stream. The resulting lipid film 
was dissolved in 1 ml of DMSO:EtOH (7:3, v/v). The lipid solution 
was injected into 9 ml of 240 mM sodium sulfate in PBS (pH 7.4) 
while being rigorously agitated to yield a 5 mM lipid solution. After 
10 freeze-thaw cycles, lipid solution was extruded via a Northern 
Lipids Extruder with a 100-nm polycarbonate nanoporous mem-
brane. After extrusion, the liposome solution was dialyzed in PBS 
(pH 7.4) using a Slide-A-Lyzer dialysis cassette (MWCO, 20 kDa) 
overnight at RT. Then, Dox was added to liposome solution to reach 
a final concentration of 1 mg/ml and incubated for 6 hours to fa-
cilitate active loading. The resulting Dox-encapsulating liposome 
solution was dialyzed in PBS (pH 7.4) using a Slide-A-Lyzer dialysis 
cassette (MWCO, 20 kDa) overnight at RT.
The surface of DCL-Dox was modified with ICAM1- and EGFR- 
neutralizing antibodies at optimal ratios via the DSPE-PEG-COOH 
anchor. EDC (2 mg) and NHS (3 mg) were mixed with 1 mmol of 
lipid (liposomes) in PBS (pH 7.4) and incubated for 6 hours at RT. A 
Slide-A-Lyzer dialysis cassette (MWCO, 20 kDa) was used to remove 
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unreacted EDC and NHS. Next, ICAM1- and EGFR-neutralizing 
antibodies at different molecular ratios (1/0, 0/1, 4.2/1, 1.5/1, and 
1/1) or the IgG isotype were added to EDC-modified liposomes at 
a molar ratio of 1:1000 (antibody/phospholipid) and incubated 
overnight at RT. Unreacted antibodies were removed by using a 
FLOAT- A-LYZER G2 dialysis tubing (MWCO, 1000 kDa). In cellular 
binding and internalization experiments, noncytotoxic FITC-dextran 
(MW, 10 kD)–encapsulating liposome (DCL-FITC) was prepared and 
tested to replace the cytotoxic DCL-Dox. The preparation process was 
similar to that of DCL-Dox except that 1 ml of lipid solution was 
added to a 9-ml of FITC-dextran solution (1 mg/ml). DiR-labeled 
DCL (DCL-DiR) was also prepared for in vivo NIR imaging experi-
ments by adding 1 mol % (mole percent) DiR to the lipid composi-
tion to prepare the dry lipid film while maintaining the rest steps as 
the same.
The density of ICAM1 and EGFR antibodies conjugated on lipo-
somes was quantified via microbead assay as described previously 
(11). Liposomes cannot be detected by flow cytometry because of 
their size, and therefore, 2-m borosilicate beads were encapsulated 
within DOPC:DSPE-PEG-COOH (95:5, mol/mol) liposomes by 
agitating small unilamellar liposomes with microbeads in PBS for 
6 hours. Microbeads were rinsed three times in PBS via suspension- 
spin cycles to separate free liposomes. Conjugation of FITC-ICAM1 
antibody, PE-EGFR antibody, or PE-IgG (nonspecific binding) to 
microbead encapsulating liposomes was performed using EDC/
NHS chemistry. Surface densities and ratios of ICAM1 and EGFR 
antibody conjugated to each microbead were determined with 
reference to Quantum Simply Cellular microbeads, which have 
defined numbers of antibody-binding sites per bead. The size and 
surface charge of DCLs and control liposomes were determined by 
dynamic light scattering on a ZetaPALS analyzer (Brookhaven 
Instruments, Holtsville, NY, USA). Liposome samples were diluted 
in PBS (pH 7.4) at a lipid concentration of 100 M at 25°C and mea-
sured with using a scattering angle of 90° and unimodal analysis. 
The zeta potential was calculated from the electrophoretic mobility 
by means of the Hemholtz- Smoluchowski relation. All measure-
ments were performed in triplicate. The morphology of DCLs was 
determined by transmission electron microscope (TEM) imaging 
on a JEOL 2100 TEM (JEOL, Peabody, MA, USA). Freshly prepared 
liposome samples (5 l, 100 M in deionized water) were dropped 
onto a 300-mesh carbon-coated copper grid (Ted Pella, Inc., Redding, 
CA, USA) and dried. All images were acquired at an accelerating 
voltage of 100 kV.
The Dox-encapsulating efficiency in DCL-Dox and control lipo-
somes was determined using a fluorescent assay. A Dox calibration 
curve was generated from a series of serially diluted free Dox stan-
dard solutions, and appropriate backgrounds were measured on a 
SpectraMaxPlus 384 UV-Visible spectrophotometer (excitation, 
485 nm; emission, 590 nm; Molecular Devices, San Jose, CA, USA). 
A 20-l liposome sample was added to 980 l of 0.5% Triton X-100 in 
a microcentrifuge tube and vortexed for 1 min. The microcentrifuge 
tube was transferred to a 37°C incubator for 1 hour. Triton X-100 is a 
surfactant that lyses liposomes. Then, 200 l of the Dox containing 
Triton X-100 solution was added to at least three wells for each sample 
of a flat bottom 96-well cell culture plate and measured for fluores-
cence. The 0.5% Triton X-100 solution without any liposome sample 
was used as a blank control. The Dox encapsulation efficiency is calcu-
lated from the following formula: encapsulated Dox concentration/
initial Dox concentration × 100.
Cellular binding and internalization assay
Quantitative analysis of liposome binding to TNBC cells was studied 
by flow cytometry analysis. Cells (106) were placed in each well of a 
six-well cell culture plate and incubated for 4 hours at 37°C with 
IgG-FITC-LP, ICAM-FITC-LP, EGFR-FITC-LP, DCL-FITC_4.2/1, 
DCL-FITC_1.5/1,DCL-FITC_1/1, ICAM-FITC-LP/EGFR-FITC-
LP mixture (4.2/1 ratio), ICAM-FITC-LP/EGFR-FITC-LP mixture 
(1.5/1 ratio), and ICAM-FITC-LP/EGFR-FITC-LP mixture (1/1 ratio) 
at a final concentration of 1 M lipids per 106 cells. All liposome-treated 
cells were washed with PBS, harvested using a 0.25% trypsin/2.6 mM 
EDTA solution, and washed three times with PBS (pH 7.4). Binding 
data were acquired using a BD FACSCalibur flow cytometer and an-
alyzed using FlowJo software. Cellular binding and uptake of DCLs 
were calculated by dividing the mean fluorescence intensity of DCL-
FITC–treated cells by that of the IgG-FITC-LP–treated cells.
The internalization ratio of DCL was evaluated using trypan 
blue quenching assay as previously reported (55, 56). Briefly, 106 
liposome-treated cells collected for flow cytometric analysis were 
equally divided into two parts. One part was directly used for flow 
cytometric measurement, and the fluorescence intensity of liposome- 
treated cells was defined as the total fluorescence including both ex-
tracellular and internalized DCLs. The other part was incubated with 
trypan blue solution (1 mg/ml) for 30 min to quench extracellular 
fluorescence and washed with PBS. The fluorescence intensity of 
trypan blue–quenched cells was defined as the internalized fluores-
cence. The internalization ratio was calculated by dividing internal-
ized fluorescence with total cell fluorescence times 100.
Cytotoxicity assay
The cytotoxicity of DCL-Dox was evaluated using a cell viability 
assay. Briefly, 104 cells (MDA-MB-231 and MDA-MB-436) were 
seeded in each well of a 96-well plate and incubated for 24 hours. 
Then, cells were treated with PBS, free Dox, IgG-Dox-LP, ICAM-
Dox-LP, EGFR-Dox-LP, and DCL-Dox at Dox concentrations rang-
ing from 0 to 50 g/ml for 6 hours. Cells were rinsed twice with 
PBS and grown for 48 hours. Cell viability was determined using a 
Dojindo cell counting kit according to the protocol provided by the 
manufacturer.
Cell proliferation assay
Five thousand cells were seeded in each well of a 96-well plate and 
grown overnight. Then, cells were incubated with PBS, IgG-LP, 
ICAM-LP, EGFR-LP, and DCL at the final liposome concentration 
of 1 M lipids per 106 cells for 48 hours. Cell proliferation was ana-
lyzed using a Dojindo cell counting kit.
Cell invasion assay
One million cells seeded in six-well plate were treated with PBS, 
IgG-LP, ICAM-LP, EGFR-LP, and DCL at the final liposome 
concentration of 1 M lipids per 106 cells for 24 hours and then 
reseeded onto 24-well Corning BioCoat Matrigel Invasion Chamber 
system with permeable support polycarbonate membrane (with 8 m 
pore size) at a cell density of 105 cells per well. DMEM without FBS 
and DMEM with 10% FBS were added to the upper and lower wells, 
respectively. Cells were allowed to invade for 20 hours. Cells on the 
reverse side of transwell membrane facing the lower chamber after 
transmigrating through the 8-m pores of transwell membrane 
were stained with Diff-Quik Stain Set. Four fields were counted for 
each sample.
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Orthotopic tumor model and treatments
Animal studies were performed according to the protocols approved 
by the Institutional Animal Care and Use Committees of Boston 
Children’s Hospital and The City College of New York. Breast tumors 
were orthotopically implanted by injecting 5 × 106 MDA-MB-231-Luc 
cells into the fourth right mammary fat pad of female nude mice 
(Charles River, Wilmington, MA, USA). Tumor-bearing mice were 
randomized into various treatment groups (n = 7 to 10 per group). 
For in vivo NIR fluorescent imaging experiments, tumors were al-
lowed to develop for 2 to 3 weeks until they were at least 200 mm3 
in volume. In vivo NIR fluorescent imaging was performed on the 
tumor-bearing mice that were intravenously injected with liposomes 
at a dosage of 20 mg lipids/kg mouse weight using tail vein injec-
tion. At 4, 24, and 48 hours after the injection, in vivo NIR fluores-
cence imaging was performed using an IVIS Lumina II system 
(Caliper, Hopkinton, MA, USA). At 48 hours after injection, mice 
were euthanized, and ex vivo NIR fluorescence intensity of various 
organs (brain, heart, liver, lung, kidney, and spleen) and excised 
tumors was measured using IVIS Lumina II.
For therapeutic efficacy experiments, MDA-MB-231-Luc tumors 
were allowed to develop for 1 to 2 weeks until they reached 100 mm3 
in volume. Mice were randomly divided into different groups and 
were treated with DCL-Dox or controls at a Dox dose of 2.5 mg/kg 
per half week. All treatments were performed intravenously via retro- 
orbital injection in 50-l volume. Tumor growth was monitored 
weekly using caliper. Twenty-four days after treatment, orthotopic 
tumors were excised to measure their mass, and various organs (brain, 
heart, liver, lung, kidney, and spleen) were collected and analyzed for 
metastasis using IVIS Lumina II.
Lung metastasis model and treatments
One million MDA-MB-231-Luc cells in 100 l of PBS were injected 
to the lateral tail vein of female nude mice to allow the formation 
of lung metastasis. At 24 hours after injection, in vivo biolumi-
nescence imaging was performed to confirm the localization of 
MDA-MB-231-Luc cells in mouse lungs using an IVIS Lumina II 
system. Then, mice were randomized into six groups (n = 8 per 
group) and received treatments with PBS (sham), free Dox, IgG-
Dox-LP, ICAM-Dox-LP, EGFR-Dox-LP, or DCL-Dox_4.2/1 
(2.5 mg/kg per dosage, twice a week) for 21 days. All injections 
for treatments were performed intravenously via retro-orbital in-
jection in 50-l volume. Lung metastasis of MDA-MB-231-Luc was 
monitored by weekly in vivo bioluminescence imaging for up to 
124 days. Mice were euthanized, and organs were excised to esti-
mate the metastatic burden. In dosage- dependent experiments, four 
dosages of DCL-Dox_4.2/1 [PBS (sham); 0.625, 1.25, and 2.5 mg/kg] 
were tested in mice with lung metastasis using the same experi-
mental protocol.
Chronic liver and renal toxicities of DCL-Dox were evaluated 
by measuring AST, ALT, creatinine, and BUN levels in mouse 
serum after treatment. At day 74 of dosage-dependent experi-
ments, mice were euthanized with CO2, and 500 l of whole blood 
was collected via cardiac puncturing. Mouse blood was transferred 
to a BD Vacutainer and incubated for 20 min at RT to allow clot-
ting. Then, serum was collected after centrifuging at 2000g for 
10 min in a refrigerated centrifuge. Serum levels of ALT, AST, 
creatinine, and BUN were determined using their activity assay 
kits purchased from Sigma-Aldrich (St. Louis, MO, USA) with pro-
vided protocols.
Statistical analysis
All of the experimental data were obtained in triplicate and are pre-
sented as means ± SD unless otherwise mentioned. One- and two-
way analysis of variance (ANOVA) with Bonferroni post hoc tests 
were used to analyze statistical variance when making multiple com-
parisons. Log-rank test was used to analyze statistical variance in 
Kaplan-Meier survival analysis. All statistical analysis was performed 
using OriginPro 8 software.
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